Oblenio Announces First Patients Dosed in Innovative Phase 1a Trial of LBL-051 in Refractory Autoimmune Diseases

Source Summary

Oblenio has dosed the first patient in its Phase 1a first-in-human trial evaluating the company's tri-specific T cell engager targeting BCMA, CD19 and CD3.